retatrutide diabetes type 1 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide Dosing Explained: What You

10 mg vial + 2 mL BAC water, 2 mg dose Vial: 10 mg | BAC water: 2 mL | Target dose: 2 mg Concentration: 10 2 = 5 mg/mL Draw volume: 2 5 = 0.4 mL U-100 units: 0.4 100 = 40 units 10 mg vial + 5 mL BAC water, 2 mg dose Vial: 10 mg | BAC water: 5 mL | Target dose: 2 mg Concentration: 10 5 = 2 mg/mL Draw volume: 2 2 = 1 mL U-100 units: 1 100 = 100 units Retatrutide Reconstitution Guide Retatrutide research vials are typically supplied as lyophilised powder

For the new study, researchers tracked insurance claims from nearly 127,000 overweight or obese adults who started GLP-1 treatment between 2019 and 2024, looking for people taking drugs like semaglutide (Ozempic/Wegovy), tirzepatide (Zepbound/Mounjaro), or liraglutide (Saxenda/Victoza)

The FDA has approved Qsymia (phentermine and topiramate) in children aged 12 years and older whose BMI is at the 95th percentile or higher, standardized for age and gender

Methodology and Sources This analysis is based on publicly available sources as of December 26, 2025: FDA communications: Compounding safety alerts, prescribing information, and regulatory guidance Novo Nordisk announcements: Wegovy pill approval, OASIS 4 trial results, pricing disclosures Independent reporting and primary sources: ABC News coverage and Novo Nordisks announcement on December 22, 2025 FDA oral Wegovy approval MEDVi terms and disclosures: Platform structure, pricing, and regulatory disclaimers Key Sources Cited: ABC News: "FDA approves Wegovy pill for weight loss" (December 22, 2025) Novo Nordisk: Official press release on FDA approval and OASIS 4 trial data (December 22, 2025) FDA Safety Communications: 20242025 alerts on compounded semaglutide dosing errors All regulatory references are based on FDA publications and third-party reporting available at the time of publication